LMR Partners’s Fulcrum Therapeutics FULC Stock Holding History

LMR Partners’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110K	Hold	30,000	–	–	﹤0.01%	1367
2026 Q1	$230K	Hold	30,000	–	–	﹤0.01%	1178
2025 Q4	$339K	Hold	30,000	–	–	﹤0.01%	1185
2025 Q3	$276K	Sell	30,000 -20,000	-40%	-$145K	﹤0.01%	1174
2025 Q2	$344K	Buy	+50,000	New	+$267K	﹤0.01%	1027
2025 Q1	–	Sell	-112,500	Closed	-$529K	–	1459
2024 Q4	$529K	Buy	+112,500	New	+$415K	﹤0.01%	833
2024 Q2	–	Sell	-17,539	Closed	-$166K	–	1175
2024 Q1	$166K	Buy	+17,539	New	+$157K	﹤0.01%	888
2021 Q4	–	Sell	-30,000	Closed	-$846K	–	1193
2021 Q3	$846K	Buy	+30,000	New	+$568K	0.01%	685

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LMR Partners's FULC Position: Q2 2026 in Review

LMR Partners held its Fulcrum Therapeutics (FULC) position steady in Q2 2026 at 30,000 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

LMR Partners first reported a position in FULC in Q3 2021 and has held it in 8 quarters since. The position peaked at $846K in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

LMR Partners held 30,000 shares of Fulcrum Therapeutics worth $110K as of Q2 2026.
LMR Partners left its Fulcrum Therapeutics share count unchanged in Q2 2026.
Fulcrum Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1367 holding.
LMR Partners first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 8 quarters since.
LMR Partners's Fulcrum Therapeutics position peaked at $846K in Q3 2021.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.